Deals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
BioMarin PharmaceuticalNASDAQ: BMRN

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has entered into an exclusive worldwide (excluding Korea) license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to co‑develop and…

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline
HKG: 6938IPO

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Broncus Medical Acquires Valgen Stake from Venus for $15 Million
Broncus MedicalHKG: 2216

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO as Surgical Robotics Leader
Edge MedicalHKG: 2675

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
Buchang PharmaceuticalsSHA: 603858

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Show More